How Analysts Feel About Nektar Therapeutics (NKTR) After Achieving 52-Week High?

Nektar Therapeutics

Nektar Therapeutics

Ny State Common Retirement Fund invested in 0.01% or 277,184 shares. Credit Suisse Ag reported 0.01% in Nektar Therapeutics (NASDAQ:NKTR). The stock presently has a consensus rating of "Buy" and an average target price of $31.82.

On November 9, 2017 Canaccord Genuity released research on NKTR by announcing an initial rating of "Buy".

Nektar Therapeutics on 9/29/2017 reported its EPS as $-0.28 with the analysts projecting the EPS of the stock as $-0.26. Prelude Capital Management Ltd Limited Liability Company reported 0.08% stake. They issued an "outperform" rating for the company. Finally, BidaskClub lowered Nektar Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, August 4th. The stock has a current ATR of 1.44.

More news: With Crude Oil Prices Rising, Florida Drivers Paying More for Gas
More news: Nathaniel Clyne ruled out until February
More news: Woman accuses George HW Bush of groping her when she was 16

Currently, the analyst consensus on Nektar Therapeutics is Strong Buy and the average price target is $34.17, representing a 5.1% upside.

Analysts expect Nektar Therapeutics (NASDAQ:NKTR) to report $-0.34 EPS on March, 7.They anticipate $0.06 EPS change or 21.43 % from last quarter's $-0.28 EPS. Nektar Therapeutics has a fifty-two week low of $11.41 and a fifty-two week high of $33.67. For NKTR, the company now has $37.97 Million of cash on the books, which is offset by $2.48 Million current liabilities. Mizuho began coverage on shares of Nektar Therapeutics in a research report on Tuesday, September 26th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.16. Nektar Therapeutics had a negative return on equity of 8,769.15% and a negative net margin of 98.87%.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Tuesday, November 7th. During the same quarter in the prior year, the firm earned ($0.32) earnings per share. Along with these its last twelve month performance is stands at 137.57% while moved 64.06% for the past six months. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and global trademark & copyright law. Shares for $33,255 were sold by Doberstein Stephen K. The insider Labrucherie Gil M sold $62,149. The shares were sold at an average price of $19.32, for a total transaction of $32,863.32. Following the sale, the chief executive officer now owns 122,908 shares in the company, valued at $1,705,963.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. On Wednesday, August 26 the stock rating was downgraded by TheStreet to "Hold". Insiders sold a total of 1,024,757 shares of company stock valued at $25,974,361 in the last ninety days. The disclosure for this purchase can be found here. Arizona State Retirement System now owns 80,945 shares of the biopharmaceutical company's stock valued at $1,582,000 after buying an additional 800 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Nektar Therapeutics by 0.6% during the 2nd quarter. Wells Fargo & Company MN lifted its position in shares of Nektar Therapeutics by 5.0% during the 3rd quarter. The company's past year sales total was 37450. 5,603 were reported by Zurcher Kantonalbank (Zurich Cantonalbank). Following the completion of the transaction, the senior vice president now owns 52,016 shares of the company's stock, valued at $1,508,464. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company's stock valued at $110,000 after acquiring an additional 692 shares during the last quarter. Genesee Valley Trust Co. now owns 12,189 shares of the biopharmaceutical company's stock valued at $209,000 after buying an additional 54 shares during the last quarter. Hedge funds and other institutional investors own 85.85% of the company's stock. BlackRock Inc. raised its stake in shares of Nektar Therapeutics by 0.9% in the second quarter. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are created to enable the development of new molecular entities that target known mechanisms of action.

Recommended News

  • Mattel unveils first Barbie to wear a hijab

    According to the Hello Hijab website, their doll hijabs serve two critical purposes. Olympic athlete to compete wearing a hijab at the 2016 Rio Olympic games.
    Detroit police respond after heated fight between officers during drug raid

    Detroit police respond after heated fight between officers during drug raid

    The fight was recorded on one officer's body camera, and the department's internal affairs division is investigating the incident. The police department said it would not comment on the incident until a statement is released later this week.

    Ben Affleck Still 'Contemplating' Matt Reeves' Batman Film

    Ahead of the domestic release of Justice League this week, Affleck is still considering if he wants to remain as Batman in the DC Extended Universe .
  • Very Illuminating Messages Between WikiLeaks and Don Jr

    Very Illuminating Messages Between WikiLeaks and Don Jr

    The messages obtained by The Atlantic were turned over to congressional investigators by Trump Jr.'s attorneys. But just 15 minutes after it was sent, as The Wall Street Journal's Byron Tau pointed out , Mr.
    You Did It: Sydney's Newest Ferry Is Honest-To-God Named Ferry McFerryface

    You Did It: Sydney's Newest Ferry Is Honest-To-God Named Ferry McFerryface

    Here's to hoping Ferry McFerryface lives a longer life along the waters of Sydney Harbour. Happily, the similar name of Ferry McFerryface was actually the next most popular option.
    Zimbabwe military chief Chiwenga in Zanu-PF purge warning

    Zimbabwe military chief Chiwenga in Zanu-PF purge warning

    Chiwenga added that Zanu PF has been hijacked by counter revolutionaries whose agenda it is to destroy Zanu PF from within. Although he did not mention the president by name, the warning is understood to be directed at the 93-year-old Mr.
  • Orioles' Trey Mancini finishes third in AL Rookie of the Year voting

    Orioles' Trey Mancini finishes third in AL Rookie of the Year voting

    Judge, 25, is also a finalist for the AL MVP (which will be announced Thursday) after leading the AL in home runs with 52. He set records for most strikeouts in the World Series , and for most strikeouts in the postseason.

    RT Says It Has Registered as Foreign Agent

    Moscow has repeatedly denied the allegations of election meddling and said it views the actions against RT as an unfriendly act. The embassy warned restrictions on the activities of Russian media "would inevitably entail immediate and reciprocal measures".

    Shell sells £1.3bn stake in Australia's Woodside Petroleum

    The sale of the shares, which represent 13.28% of the issued capital of Woodside, is expected to be complete on November 14. The company said that represented 64% of its interest in Woodside and 8.5% of the issued capital in Woodside.
  • Seahawks bring back Byron Maxwell to help replace Richard Sherman at cornerback

    Seahawks bring back Byron Maxwell to help replace Richard Sherman at cornerback

    The Seattle Seahawks are reportedly replacing one member of the original Legion of Boom with another. Maxwell fell out of favor with the Dolphins after losing his starting job earlier this season.
    DC Comics Fires Editor Eddie Berganza Over Assault Allegations

    DC Comics Fires Editor Eddie Berganza Over Assault Allegations

    The firing comes after another BuzzFeed News report first detailed the allegations from two former DC employees. Several former and current DC employees BuzzFeed spoke with insist Berganza has fully reformed and repented.
    Spider-Man spinoff film Morbius: The Living Vampire in development

    Spider-Man spinoff film Morbius: The Living Vampire in development

    Following his debut in The Amazing Spider-Man, the character was given his own series for a time and was featured in other titles. As such, they've decided to make some spin-off movies using these characters that won't include Spider-Man in them.

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.